Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike
- PMID: 18691545
- DOI: 10.1016/j.ccr.2008.07.008
Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike
Abstract
In this issue of Cancer Cell, Zunder et al. (2008) describe surprising findings from investigating inhibitor-resistant mutations in the affinity pocket of p110 alpha of phosphatidylinositol 3-kinase (PI3K). Information on these critical residues provides a road map for generating novel PI3K inhibitors that can overcome the anticipated resistance mutations.
Comment on
-
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.Cancer Cell. 2008 Aug 12;14(2):180-92. doi: 10.1016/j.ccr.2008.06.014. Cancer Cell. 2008. PMID: 18691552 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources